Matinas Biopharma Holdings, Inc. (MTNB) financial statements (2020 and earlier)

Company profile

Business Address 1545 ROUTE 206 SOUTH
BEDMINSTER, NJ 07921
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments28127433
Cash and cash equivalents22127433
Short-term investments6     
Restricted cash and investments000   
Prepaid expense 11   
Other undisclosed current assets2  000
Total current assets:30138543
Noncurrent Assets
Finance lease, right-of-use asset0
Operating lease, right-of-use asset4
Property, plant and equipment222000
Long-term investments and receivables  1100
Long-term investments  1100
Intangible assets, net (including goodwill)44444 
Goodwill11111 
Intangible assets, net (excluding goodwill)33333 
Restricted cash and investments00    
Total noncurrent assets:1076551
TOTAL ASSETS:4020141083
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities332111
Accounts payable101000
Accrued liabilities211111
Interest and dividends payable 1    
Debt000000
Deferred revenue and credits000 
Total current liabilities:332111
Noncurrent Liabilities
Long-term debt and lease obligation4000 0
Finance lease, liability0
Capital lease obligations000 0
Operating lease, liability4
Liabilities, other than long-term debt01111 
Deferred rent credit 1
Deferred tax liabilities, net0111 
Deferred income tax liabilities0
Other undisclosed noncurrent liabilities  1   
Total noncurrent liabilities:412110
Total liabilities:744321
Stockholders' equity
Stockholders' equity attributable to parent, including:331611762
Preferred stock   6  
Common stock000000
Additional paid in capital1137256362916
Accumulated other comprehensive loss(0)     
Accumulated deficit(84)(66)(51)(35)(23)(14)
Other undisclosed stockholders' equity attributable to parent4106   
Total stockholders' equity:331611762
TOTAL LIABILITIES AND EQUITY:4020141083

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:000 0 
Operating expenses(19)(15)(17)(8)(10)(10)
Operating loss:(19)(15)(17)(8)(10)(10)
Nonoperating income (expense)100(0)0(0)
Investment income, nonoperating1 1110
Debt instrument, convertible, beneficial conversion feature   4  
Interest and debt expense(0)(0) (0)(0)(0)
Loss from continuing operations before income taxes:(18)(15)(16)(8)(10)(10)
Income tax expense (benefit) 10  (0)
Net loss:(18)(14)(16)(8)(10)(11)
Other undisclosed net income attributable to parent101111
Net loss attributable to parent:(17)(14)(15)(8)(9)(10)
Preferred stock dividends and other adjustments(0)(1) (4)  
Other undisclosed net loss available to common stockholders, basic(1) (17)   
Net loss available to common stockholders, diluted:(18)(15)(33)(12)(9)(10)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(18)(14)(16)(8)(10)(11)
Other comprehensive loss(0)     
Comprehensive loss:(18)(14)(16)(8)(10)(11)
Other undisclosed comprehensive income, net of tax, attributable to parent1     
Comprehensive loss, net of tax, attributable to parent:(17)(14)(16)(8)(10)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: